Activation of AMPK/SIRT1 axis is required for adiponectin-mediated preconditioning on myocardial ischemia-reperfusion (I/R) injury in rats

Maria Assunta Potenza¹, Luca Sgarra², Carmela Nacci¹, Valentina Leo¹, Maria Antonietta De Salvia¹, Monica Montagnani¹*  
¹ Department of Biomedical Sciences and Human Oncology-Pharmacology Section, Medical School-University of Bari "Aldo Moro", Bari, Italy, ² Department of Emergency and Organ Transplantation-Section of Cardiovascular Diseases, Medical School-University of Bari "Aldo Moro", Bari, Italy  
* monica.montagnani@uniba.it

Abstract

Background
Adiponectin (AD) cardioprotective activities are mediated by AMPK, a fuel-sensing molecule sharing common targets and cellular activities with SIRT-1. Whether AD preconditioning may involve SIRT-1 activity is not known; however, the protective role of SIRT-1 during ischemia and the potential interplay between AMPK and SIRT-1 suggest this possibility.

Methods
Isolated hearts from male Sprague-Dawley rats (n = 85) underwent ischemia/reperfusion (I/R, 30/180 min). Preconditioning with resveratrol (RSV, SIRT-1 activator) was compared to preconditioning with AD alone, or in combination with compound C (CC, AMPK inhibitor) or sirtinol (STN, SIRT-1 inhibitor). For each heart, left ventricular end-diastolic pressure (LVEDP), left ventricular developed pressure (dLVP), coronary flow (CF) and left ventricular infarct mass (IM) were measured, together with the phosphorylation/activation status of AMPK, LKB1, eNOS and SIRT-1, at the beginning (15 min) and at the end (180 min) of reperfusion.

Results and conclusions
When compared to I/R, both RSV and AD improved cardiac function and reduced IM (p < 0.01, p < 0.05, respectively). Cardioprotective effects of AD were completely reversed in the AD+CC group, and significantly attenuated in the AD+STN group. Both RSV and AD increased eNOS, AMPK and LKB1 phosphorylation (for each parameter: p < 0.05 vs. I/R, in both RSV and AD treatment groups) at 15 min of reperfusion, and SIRT-1 activity at the end of reperfusion (p < 0.01, p < 0.05 vs. I/R, respectively). Interestingly, AD-mediated phosphorylation of AMPK and LKB1, and SIRT-1 deacetylation activity was markedly reduced in both the AD+CC and AD+STN groups (p < 0.05 vs. AD). Thus, AD-mediated
cardioprotection requires both AMPK and SIRT-1 signaling pathways, that act as a component of a cycle and regulate each other’s activities.

Introduction

The extension of the myocardial infarct size resulting from both ischemia and reperfusion (I/R) injury is a key determinant for the prognosis of patients who survive an acute myocardial infarction (MI) [1]. The molecular plasticity of the heart to adapt to I/R stress has encouraged the exploration of conditioning strategies (known as pre- and post-conditioning) that may enhance cardioprotection by facilitating adaptative responses and ameliorating the heart functional recovery [2]. However, and despite the large number of signaling pathways identified so far, pharmacologic approaches to attenuate the consequences of I/R injury are still of limited efficacy and fail to translate into useful clinical treatments. In part, this may be due to specific alterations in fundamental cellular signaling cascades that the same risk factors predisposing to the development of ischemia (e.g., atherosclerosis, hypertension, diabetes) play in the response to cardioprotective interventions [3]. Thus, investigation on cellular mechanisms ensuring cardioprotective effect from I/R injury under specific conditions is still ongoing.

During ischemia [4], the reduced oxygen availability causes intracellular acidosis and impairs cardiac energy metabolism by increasing levels of inorganic phosphates, resulting in the unbalance of both AMP/ATP and NAD/NADH ratio [5]. These metabolic changes affect, among others, the AMP-activated protein kinase (AMPK) [6] and the NAD$^+$-dependent deacetylase sirtuin-1 (SIRT-1) [7], two fuel-sensing molecules sharing common intracellular targets [8–10], and regulating processes as survival and cellular longevity [11], cellular energy and metabolism [12], inflammation [13], apoptosis and ROS reduction [14], mitochondrial biogenesis and function [15].

The critical relevance of AMPK in cardioprotection has been persistently demonstrated by the severe heart contractile dysfunction under AMPK inactivation or deletion [16,6,17]. AMPK promotes cell survival in ischemic heart by inducing cardiomyocyte autophagy, by attenuating ER stress, and by decreasing myocardial oxygen consumption via endothelial nitric oxide synthase (eNOS)-mediated NO production [18–20].

A number of studies suggest that SIRT-1, as AMPK, is activated in response to changes in nutrient availability [21,22] and energy expenditure [12,23]. In mouse skeletal muscle, SIRT-1 activity is enhanced by AMPK, that increases cellular NAD$^+$ levels and NAD/NADH ratio and favours deacetylation of SIRT-1 downstream targets [23]. Interestingly, Liver Kinase B1 (LKB1), a key upstream activator of AMPK, has been identified among SIRT-1 deacetylation targets [24], and SIRT-1-dependent dysregulation of the LKB1-AMPK pathway has been implied in the development of dysmetabolic conditions. In the heart, SIRT-1 protects cardiomyocytes against oxidative stress, apoptosis, and aging [25,26] and cardiac SIRT-1 overexpression limits the extent of infarct size during I/R injury [27]. Coherently, genetic or pharmacological abrogation of SIRT-1 reduces the beneficial effects of ischemic preconditioning in hearts subjected to I/R injury [28–30].

Heart AMPK may be activated by several mediators including adiponectin (AD), whose circulating levels are markedly reduced under obesity, diabetes and insulin-resistance conditions, as well as in patients with hypertension, coronary artery disease and myocardial infarction [31–33]. Beside anti-inflammatory [34,35], antiatherogenic ad vasorelaxant properties promoted by stimulation of eNOS [36,37], AD exerts direct cardioprotective effects mediated by
signaling cascades involving AMPK and LKB1 [38]. In rat hearts subjected to I/R injury, activation of the AMPK/AKT/eNOS pathway by exogenous AD limits the contractile dysfunction and decreases the infarct size both in preconditioning [39] as well as in postconditioning administration [40]. Accordingly, AD-knockout mice demonstrate impaired AMPK activation during ischemia and increased susceptibility to ischemic injury [41], reverted by adeno-viral-mediated AD expression [41]. Whether cardioprotection induced by exogenous AD administration may involve SIRT-1 activity is not known; however, the protective role of SIRT-1 during ischemia and the potential interplay between AMPK and SIRT-1 suggest this possibility. Therefore, this study was planned to investigate the hypothesis that AD-mediated preconditioning may protect rat hearts subjected to I/R injury via activation of the AMPK/SIRT1 axis.

**Materials and methods**

All procedures in animals were approved by the Committee on the Ethics of Animal Experiments of the University of Bari and performed under Authorization for the Use of Laboratory Animals of Ministry of Health (Italian Government, prot.n. 216/2016-PR).

**Animals**

A total of 85 adult male Sprague-Dawley (SD) rats (Envigo, Udine-Italy) weighing 250–300 g were housed in a temperature-, humidity- and light-controlled room of the Department animal facility. Rats were randomly assigned to treatments illustrated under “Experimental protocol”, anesthetized with sodium pentobarbital (80 mg/kg body weight i.p.), heparinized (400 UI/100 g body weight i.p.) and euthanized by cervical dislocation. All efforts were made to minimize animal suffering.

Hearts from SD rats were isolated and mounted on a Langendorff perfusion system (Radt- noti LLC, USA), as previously described [42]. Briefly, excised hearts were immediately subjected to aortic cannulation and perfused with modified Krebs-Henseleit solution (composed of (mmol/l): 118.5 NaCl; 4.7 KCl; 1.2 MgSO\(_4\); 1.2 KH\(_2\)PO\(_4\); 1.25 CaCl\(_2\)(H\(_2\)O); 25 NaHCO\(_3\); 11 glucose) continuously gassed with a mixture of 95% O\(_2\) and 5% CO\(_2\) (pH 7.4) at 37°C. The perfusion pressure (PP) was kept constant at 80 mmHg for the whole experimental procedure.

Hemodynamic parameters evaluated during reperfusion included isovolumetric recordings of left ventricular systolic (LVSP) and end-diastolic (LVEDP) pressures obtained from a balloon catheter inserted into the left ventricle through the auricle (LVEDP set to 5–10 mmHg at the beginning of the stabilization period). Coronary flow was measured by timed collection of the coronary effluent. Left ventricular developed pressure (dLVP) was calculated as dLVP = LVSP—LVEDP. The rate of pressure product (RPP) was not included among functional parameters measuring post-ischemic heart recovery: although representing an important index of cardiac effort, RPP may indicate oxygen consumption and myocardial workload only in the presence of a positive force–frequency relationship. However, isolated rodent hearts demonstrate a negative force–frequency relationship [43], and the potential significance of RPP in the Langendorff-perfused isolated rat heart is uncertain.

All data were acquired at a sampling rate of 1 kHz by a 4-channel PowerLab system (ADInstruments, UK) and analyzed using LabChart 7 Pro Software (ADInstruments, UK). A side arm attached to a chamber in connection to the aortic cannula was used for drugs administration at the onset of ischemia.

**Experimental protocol**

Each heart (10 hearts/group) was allowed to stabilize for 20 min, and then subjected to 30 min of global no-flow ischemia followed by 180 min of reperfusion. Only hearts with LVSP
between 60–160 mmHg and coronary flow 8–16 ml/min were studied. Thus, in each group, the number of hearts studied indicates the difference between the initial number of hearts assigned and the number of hearts excluded (10 –x/ group). Pharmacological preconditioning was obtained by bolus infusion of drugs (3 mL/1 min), alone or in combination, directly into the aortic cannula at the onset (during the first minute) of ischemia. According to specific protocols, the hearts were randomly exposed to the following treatments: ischemia/reperfusion (I/R) (vehicle-treated; n = 7), human recombinant adiponectin (AD) (Adipogen; 3 μg/mL; n = 6), resveratrol (RSV) (Sigma-Aldrich, 10 μM; n = 8), sirtinol (STN) (Sigma-Aldrich, 10 μM; n = 6); compound C (CC) (Sigma-Aldrich, 10 μM; n = 5), AD+STN (n = 6), and AD+CC (n = 6). For WB experiments on signaling pathways activation during the early reperfusion time (15 min), 3 additional hearts/group were used for I/R, AD, RSV, AD+STN and AD+CC treatments.

Stock solutions of RSV (50 mM), STN (1 mM) and CC (12.5 mM) were prepared in pure DMSO. Final dilutions of these drugs were prepared in modified Krebs-Henseleit solution immediately before use and contained DMSO 0.1%, according to recommendation related to potential toxic effects for DMSO concentrations > 1% [44]. AD was directly dissolved in modified Krebs-Henseleit solution. Recombinant human AD shows overlapping biological activity among human and rodent species [45]. Haemodynamic parameters and coronary flow were recorded twice before ischemia, and after 5, 15, 30, 45, 60, 90, 120 and 180 min of reperfusion.

**Determination of area at risk and infarct size**

At the end of reperfusion period, hearts were incubated in freshly prepared 2,3,5 triphenyltriazolium chloride (TTC 1% w/v phosphate buffer pH 7.4, 37° C, 20 min) and then weighed and frozen (−80° C, 30 min). Each heart was subsequently sliced in transverse sections (approximately 1.5 mm thick), and each slice weighed and scanned on both sides by a flat-bed scanner (Epson 3490). The infarct area on each color image (TTC unstained) was traced in a blind fashion and measured by planimetry (Image-Tool 2.0 Software NIH, USA). Area at risk (AAR, representing total infarct area with respect to total muscle mass) was calculated by the sum of individual slice weights according to the following formula: \( \frac{A_{In}}{A_{ARn}} \times \frac{W_{n}}{W_{total}} \), where AI is the infarct area of each slice (n = 7), Wn is the weight of the respective section (n) and Wtotal is the sum of all slice weights [46].

**Tissue processing**

*Western Blot analysis*—In another set of experiments, hearts (n = 3/group) were assigned randomly to pharmacological treatments previously described, and subjected to I/R injury. At the beginning of reperfusion period (15 min), samples of the left ventricular tissue were freeze-clamped in liquid nitrogen and then stored at -80° C until further analysis. Frozen samples were homogenized on ice in cold RIPA lysis buffer containing 1% Nonidet P-40, 0.5% Sodium deoxycholate, 0.1% SDS, 50 KIU aprotinin, 100 mM sodium orthovanadate, 10 mg/ml PMSF, and then centrifuged at 4° C for 15 min at 13,000 g. Protein level was determined by Bradford’s method [47]. Equal amounts of proteins (100 μg) were separated by 10% SDS-PAGE and subjected to immunoblotting with the following primary antibodies (dilution 1:1000): eNOS, (Transduction Laboratories, Lexington KY), Ph-eNOS, AMPK, Ph-AMPK, LKB1, Ph-LKB1, Ph-SIRT-1 (Cell Signaling Technology, MA), SIRT-1 (Santa Cruz Biotechnology, Inc, CA). Incubation with HRP-linked antimouse or antirabbit secondary antibodies (Santa Cruz Biotechnology Inc., CA) (1:3000) was performed for 1 h at room temperature. Immunoblotting results were visualized by Molecular Imager ChemiDoc XRS System (Bio-Rad Laboratories, CA). Images were captured with QuantityOne Software (Bio-Rad Laboratories, CA) and blots quantified by scanning densitometry (ImageJ, NIH, Bethesda, MD).
SIRT-1 activity (deacetylation) assay—For SIRT-1 deacetylation assay, at the end of reperfusion period (180 min), samples of the left ventricular tissue (the tip from hearts of each group) were freeze-clamped in liquid nitrogen and then stored at -80˚C until further analysis. SIRT-1 deacetylation activity in vitro was determined by fluorimetric analysis with a specific fluorescent kit (Enzo Life Sciences, Italy), according to manufacturer’s instructions. This assay uses a small lysine-acetylated peptide comprising amino acids 379–382 of human p53, as substrate. The assay’s fluorescence signal is generated in proportion to the amount of deacetylation of the lysine corresponding to Lys-382, a known in vivo target of SIRT-1 activity, and this process is dependent on the addition of exogenous NAD⁺. Briefly, heart tissue (50–100 mg) was homogenized, and 25 μL homogenate incubated with 15 μL Fluor de Lys-SIRT-1 substrate (50 μM) and NAD⁺ (100 μM) for 60 min at 37˚C. The reaction was stopped by adding a solution containing Fluor de Lys Developer and 2 mmol/L nicotinamide, and the fluorescence was monitored at 360 nm (excitation) and 460 nm (emission). Changes in fluorescence, measured as arbitrary fluorescence units (AFU) per min, was normalized to the amount of total protein in each sample (AFU/min/μg protein).

Statistical analysis
A power analysis was prospectively conducted to determine the number of rats needed. Based on coefficients of variation calculated for similar studies, a sample size of 5 (in each group) was sufficient to detect 10% differences in infarct area extent (α = 0.05) with a power of 0.80. All data are expressed as mean ± standard error (SE) of n experiments (n = number of rats). For evaluation of functional parameters, statistical significance between groups was measured by two-way repeated measures ANOVA (analyzing effect of time, group and time by group interaction), followed by Tukey test for multiple comparison, as appropriate. For infarct mass, SIRT-1 deacetylation activity and immunoblotting experiments, results between groups were compared by one-factor ANOVA followed by Bonferroni correction. Values of p < 0.05 were considered to indicate statistical significance. All analysis was performed using Statistica Release 7 (Statsoft Institute Inc).

Results and discussion
Ischemic preconditioning, although effective in experimental studies, has limited clinical applicability. Therefore, pharmacological treatments that may reproduce the protective effects of this approach have been regarded as a more feasible strategy against acute ischemic insult [2,48–51]. However, assessment of any potential benefit from pharmacological preconditioning must preliminary exclude whichever protective effect exerted by the manoeuvre of conditioning per se. Thus, before evaluating the mechanisms involved in AD-mediated cardioprotection, hearts exposed to 30 min ischemia followed by 180 min reperfusion (I/R group) were first compared with hearts infused with vehicle alone (3 mL/1 min) at the onset of ischemia; both functional parameters and the extent of infarct area did not significantly differ between hearts from these two groups (S1 Fig). Therefore, in all subsequent experiments, the effect of each individual treatment was compared with data obtained in the I/R group. As shown in Table 1, baseline functional parameters from isolated rat hearts subjected to distinct pharmacological treatments were not significantly different.

AD preconditioning improves post-ischemic recovery of ventricular function in a AMPK and SIRT-1-dependent fashion
To investigate the involvement of AMPK/SIRT-1 on AD preconditioning, functional parameters of left ventricular function obtained in hearts exposed to AD were compared with those
achieved in hearts infused with RSV, known to activate SIRT-1 and used here as positive control. Previous studies have shown that RSV, a natural polyphenol found in red wine and grapes, is able to improve post-ischemic cardiac function by enhancing the anti-oxidative capacity of the heart [52]: these beneficial effects have been ascribed, at least in part, to activation of SIRT-1-dependent transcriptional regulatory mechanisms [26,53] resulting in upregulated AMPK expression and improved cardiac retrieval [54].

During the whole reperfusion time (180 min), LVEDP, an index of left ventricular contractility whose values increase proportionally to the degree of ventricular failure, was significantly lower in hearts from RSV group when compared to I/R group ($p < 0.01$, Fig 1A). Concomitantly, systolic left ventricular pressure (LVP max), indicating post-ischemic systolic functional recovery, was substantially higher ($p < 0.01$ vs. I/R group, S2 Fig). Accordingly, the post-ischemic dLVP, which summarizes systolic and diastolic pressure values, was significantly improved in RSV group ($p < 0.01$ vs. I/R, Fig 1B). No changes were observed in coronary flow between hearts exposed to RVS or I/R (Fig 1C).

Consistent with previous studies reporting the protective effects of AD in rodent hearts [39,41], AD preconditioning decreased LVEDP during the whole reperfusion period, with LVEDP values substantially overlapping those obtained in hearts exposed to RSV preconditioning ($p < 0.01$ vs. I/R, Fig 1A). AD preconditioning also significantly improved dLVP with respect to I/R group ($p < 0.05$ vs. I/R, Fig 1B), although dLVP in the AD group and RSV group did not completely overlap ($p < 0.05$ vs. RSV, Fig 1B). Interestingly, during the first 60 min of reperfusion, coronary flow tended to increase in AD group with respect to I/R group (Fig 1C), though this effect did not reach statistical significance.

Taken together, when compared to hearts exposed to I/R alone, parameters of left ventricular function were significantly ameliorated in hearts subjected to preconditioning with AD or RVS, thus supporting the hypothesis that both these compounds might activate similar pathways.

The involvement of AMPK in AD-mediated post-ischemic left ventricular recovery was verified by comparing results from hearts infused with AD alone and AD in combination with compound C (CC), a specific inhibitor of AMPK (Fig 2A–2C). As expected, preconditioning with CC alone did not improve (but rather worsened) parameters of the left ventricular function observed in hearts from I/R group (Fig 2A–2C).

In hearts concomitantly treated with AD+CC, values of LVEDP were significantly higher than in the AD group during the whole reperfusion interval ($p < 0.01$), and similar to those measured in the I/R group (Fig 2A). On the other hand, values of dLVP obtained under AD

| Groups   | Body Weight (g) | Heart Weight (g) | dLVP (mmHg) | LVEDP (mmHg) | Heart Rate (BPM) | Flow Rate (ml/min) |
|----------|-----------------|------------------|-------------|--------------|-----------------|--------------------|
| I/R      | 380 ± 10        | 1.02 ± 0.4       | 86.5 ± 2.3  | 11.6 ± 2     | 265 ± 29        | 12 ± 5             |
| RSV      | 378 ± 11        | 0.98 ± 0.2       | 84.9 ± 8.1  | 9.5 ± 5      | 275 ± 31        | 13 ± 2             |
| AD       | 384 ± 12        | 0.93 ± 0.5       | 92.2 ± 4.4  | 11.1 ± 2     | 279 ± 19        | 11 ± 3             |
| STN      | 390 ± 10        | 0.99 ± 0.2       | 92.2 ± 9.9  | 10.5 ± 2     | 279 ± 29        | 12 ± 3             |
| CC       | 385 ± 11        | 0.97 ± 0.1       | 99.5 ± 9.9  | 11.4 ± 2     | 273 ± 24        | 11 ± 3             |
| AD + CC  | 392 ± 13        | 0.95 ± 0.4       | 129.3 ± 20.2| 13.7 ± 1     | 265 ± 30        | 11 ± 4             |
| AD + STN | 385 ± 14        | 0.94 ± 0.1       | 98.3 ± 14.1 | 12.3 ± 2     | 269 ± 27        | 11 ± 2             |

Values represent the mean ± SD for values measured during the last 7 min of stabilization prior to ischemia. dLVP developed left ventricular pressure, LVEDP left ventricular end-diastolic pressure. No significant difference was found between groups (one-way ANOVA test).

https://doi.org/10.1371/journal.pone.0210654.t001
Fig 1. AD preconditioning improves post-ischemic recovery of ventricular function with effects partially overlapping those induced by RSV preconditioning. Hearts preconditioned with adiponectin (AD) were compared to hearts exposed to vehicle-administration (I/R) or resveratrol (RSV), used as a positive control of SIRT-1 activation. 

A. **Diastolic function.** Left ventricular end diastolic pressure (LVEDP, mmHg) during the 180 min of reperfusion following 30 min of global ischemia (\( \ast \ast p < 0.01 \) vs. I/R).

B. **Systolic function.** Percent variation of developed left ventricular pressure (dLVP) for each group during the 180 min of reperfusion, respectively (\( \ast \ast p < 0.05 \) AD vs. I/R, \( \ast \ast \ast p < 0.01 \) RSV vs. I/R).

C. **Percent variation of coronary flow** during the 180 min of reperfusion. Two-way repeated measures ANOVA was employed to determine the main effect of time, group and time by group interaction.

https://doi.org/10.1371/journal.pone.0210654.g001
Fig 2. The AD-mediated post-ischemic left ventricular recovery depends on AMPK activation. Hearts preconditioned with AD were compared to hearts infused with compound C, a specific inhibitor of AMPK, alone (CC), or in combination with AD (AD + CC). A. **Diastolic function.** Left ventricular end diastolic pressure (LVEDP, mmHg) during the 180 min of reperfusion (*) \( p < 0.01 \) AD vs AD + CC) B. **Systolic function.** Percent variation of developed left ventricular pressure (dLVP) for each group during the 180 min of reperfusion (* \( p < 0.05 \) AD vs AD + CC). C. Percent variation of **coronary flow** during the 180 min of reperfusion. Two-way repeated measures ANOVA was employed to determine the main effect of time, group and time by group interaction.

https://doi.org/10.1371/journal.pone.0210654.g002
preconditioning were decreased in the AD+CC group (\( p < 0.05 \) vs. AD group, Fig 2B); moreover, the increased coronary flow observed in the AD group during the first 60 min of reperfusion was lost in the AD+CC group (Fig 2C). These results reinforce the importance of AMPK activity in AD-mediated effects, consistent with the key role of AMPK in modulating energy homeostasis of isolated cardiomyocytes [55] and whole heart [56,57] in response to ischemic stress [16] and cardiac hypertrophy [58].

To evaluate the potential contribution of SIRT-1 in AD-mediated preconditioning, functional parameters of post-ischemic recovery obtained in hearts treated with AD alone were compared with those exposed to AD in combination with STN, a well-known inhibitor of NAD-dependent histone deacetylase SIRT-1. Exposure to STN alone did not modify LVDEP, dLVP or coronary flow with respect to I/R group (Fig 3A–3C). On the other hand, in hearts subjected to AD+STN preconditioning, values of LVEDP during whole reperfusion period were significantly higher with respect to LVEDP observed in hearts receiving AD alone (\( \ast \ast p < 0.01 \), Fig 3A). Surprisingly, LVP max, indicating post-ischemic systolic functional recovery, was slightly increased in AD+STN group during the second and third hour of reperfusion (\( p < 0.05 \) at 90, 120, 180 min vs. respective values in the I/R and AD groups, S2 Fig). As a consequence, at the same time-intervals, dLVP values obtained under concomitant administration of AD+STN were higher than in the I/R group (\( p < 0.05 \) at 90, 120, 180 min vs. respective values, Fig 3B), and did not significantly differ from the AD group (Fig 3B).

On the other hand, coronary flow was reduced during the second and third hour of reperfusion in hearts receiving AD+STN (\( \ast p < 0.05 \) vs. AD group, Fig 3C). Taken together, these findings suggest that inhibition of SIRT-1 by STN modifies only partially the AD-mediated effects, with a more pronounced effect on global left ventricular recovery than on isolated systolic function, and a negative effect on coronary perfusion.

**Inhibition of either AMPK or SIRT-1 activity abrogates the beneficial effects of AD-mediated preconditioning on infarct mass extension**

Besides functional parameters, the most reliable evaluation of the effectiveness for a cardioprotective strategy is based on the extent of the infarct area. Thus, at the end of the reperfusion interval, the percent of ischemic area was compared among hearts exposed to various treatments. Consistent with the improved cardiac performance suggested by parameters of left ventricular function, the infarct size was significantly smaller in hearts exposed to both RVS or AD preconditioning when compared to I/R group (16 ± 4.1% and 19.6 ± 1.4%, respectively, vs. 28.1 ± 1.1%; \( p < 0.01 \)) (Fig 4A). As expected, preconditioning with both STN or CC alone did not significantly reduce the extent of infarct area with respect to hearts exposed to I/R (\( p = 0.9; \) \( p = 0.79 \), respectively) (Fig 4A). Interestingly, the cardioprotective effects of AD preconditioning were lost in hearts concomitantly infused with either AD+STN or AD+CC (\( p < 0.05 \) vs. AD group) (Fig 4A).

Concomitantly, SIRT-1 activity was evaluated by measuring the amount of Lys-382 deacetylation under each specific treatment (Fig 4, panel B). SIRT-1 requires NAD\(^+\) as a substrate for its enzymatic activity, and RSV administration at the onset of ischemia has been shown to increase NAD\(^+\) bioavailability and SIRT-1 function, to improve left ventricular functional recovery and reduce the infarct mass [59]. In line with the significant amelioration of post-ischemic recovery, SIRT-1 activity was significantly increased in heart homogenates exposed to RSV preconditioning (\( p < 0.01 \) vs. I/R group). Qualitatively similar results were obtained in hearts exposed to AD preconditioning, where SIRT-1 activity was approximately 3-times higher than under control conditions (\( \ast p < 0.05 \) vs. I/R group).
Fig 3. The AD-mediated post-ischemic left ventricular recovery partially depends on SIRT-1. Hearts preconditioned with AD were compared to hearts infused with sirtinol, a specific inhibitor of SIRT-1, alone (STN), or in combination with AD (AD + STN). 

A. **Diastolic function.** Left ventricular end diastolic pressure (LVEDP, mmHg) during the 180 min of reperfusion (**p < 0.01 AD vs AD + STN)).

B. **Systolic function.** Percent variation of developed left ventricular pressure (dLVP) for each group during the 180 min of reperfusion (*p < 0.05 at 90, 120, 180 min AD vs AD + STN)).

C. **Coronary flow.** Percent change in coronary flow for each group during the 180 min of reperfusion (*p < 0.05 at 180 min AD vs AD + STN)).
Unsurprisingly, SIRT-1 activity was unchanged in hearts treated with STN, as well as in hearts exposed to CC preconditioning, when compared to hearts of the I/R group. The concomitant treatment with AD+STN markedly reduced the AD-mediated activation of SIRT-1 (\( p < 0.05 \) vs. AD group). Finally, a significant difference in SIRT-1 activity was also measured in hearts exposed to AD+CC with respect to AD alone (\( p < 0.05 \)). These findings strongly support the ability of AD to trigger SIRT-1 activity, and reinforce the hypothesis that the AD-dependent cardioprotection might be mediated, at least partially, via SIRT-1 signaling. Interestingly, results obtained in the AD + CC group suggest that, under AMPK inhibition, the AD ability to activate SIRT-1 is impaired; this implies that AMPK activation is required to achieve a full activation of SIRT-1, and further strengthens the existence of an AMPK/SIRT-1 cycle responsible for AD preconditioning.

**AD requires a different timing for complete activation of AMPK, LKB1, eNOS and SIRT-1 signaling pathways in ischemic hearts**

Although supportive of an AMPK/SIRT-1 involvement in AD-mediated cardioprotection, the observations described above do not provide direct evidence of a specific molecular activation, nor help to clarify whether AMPK and SIRT-1 are subsequently or concomitantly recruited by AD. Signaling cascades involved in intracellular events occurring immediately after exposure to the drug of interest were therefore evaluated 15 min after reperfusion. Total and phosphorylated protein levels of eNOS (at Ser 1177), SIRT-1 (at Ser 47), AMPK (at Thr172) and LKB1 (at Ser 428), an upstream kinase of AMPK and downstream target of SIRT-1, were compared in homogenates from hearts exposed to I/R, RSV and AD, alone and in combination with CC or STN (Fig 5).

Protein expression of SIRT-1, eNOS, AMPK and LKB1 did not vary among groups (Fig 5, panel B). In hearts treated with RSV (Fig 5, column 2), levels of phosphorylated eNOS, AMPK and LKB1 were increased with respect to I/R group (\( p < 0.05 \)); conversely, despite a weak increase, phosphorylated SIRT-1 was not significantly higher with respect to I/R group (\( p = 0.12 \); Fig 5, column 1). In homogenates of hearts subjected to AD preconditioning (Fig 5, column 3), SIRT-1 phosphorylation levels did not appear increased with respect to I/R group (\( p = 0.22 \)); conversely, phosphorylation levels of eNOS, and of AMPK and LKB-1 were significantly higher (\( +p < 0.01, +p < 0.05 \), respectively) when compared to I/R group (Fig 5, column 3).

As expected, no change in SIRT-1 phosphorylation was detected in hearts concomitantly administered with AD+SNT (Fig 5, column 4); phosphorylation levels of eNOS were higher than in the I/R group (\( p < 0.05 \), but reduced if compared to the AD group (\( p < 0.05 \)); both AMPK and LKB1 phosphorylated levels were similar in the AD+SNT and in the I/R groups, and lower than in the AD group (\( p < 0.05 \)). Finally, in the AD+CC group (Fig 5, column 5), administration of an AMPK inhibitor (CC) did not affect SIRT-1 phosphorylation, but completely reversed the ability of AD to increase phosphorylation of eNOS, AMPK and LKB1.

Collectively, these observations confirm that the AD-mediated cardioprotective effects require the early activation of both AMPK and LKB1, concurring to increase the AD-mediated eNOS phosphorylation. Although no significant variation in phospho-SIRT-1 was detected under these conditions, the impaired AMPK and LKB1 phosphorylation, along with the
Fig 4. Inhibition of either AMPK or SIRT-1 activity abrogates AD-mediated preconditioning on infarct mass extension. A. Upper panel. Quantification of necrotic tissue, expressed as percentage of the left ventricular mass, in hearts exposed to various treatments at the end of the reperfusion interval. Statistical differences between groups were evaluated by one-factor ANOVA followed by Bonferroni correction. Values are expressed as mean ± SEM (** p < 0.01; * p < 0.05). A. Lower panel. Representative images of left ventricular sections quantified in panel above are shown. Hearts were cut into transverse slices and stained with TTC to differentiate necrotic.
limited eNOS phosphorylation observed in the AD+STN group, suggest that SIRT-1 is required for full activation of the AD-mediated signaling pathways and subsequent cardioprotection. On this respect, it is important to take into account that SIRT-1 possesses at least 13 serine/threonine residues known to be target of distinct kinases (including LKB1, JNK and Cdk1), that SIRT-1 deacetylase activity increases proportionally to global phosphorylation levels, and that phosphorylation on specific sites increases the suitability of SIRT-1 as a substrate for additional kinases [60]. It is possible that SIRT-1 phosphorylation at Ser 47 might not be detectable at the early phase of post-ischemic reperfusion; however, and although SIRT-1 deacetylation activity was not directly measured 15 min after reperfusion, acetylation levels on NF-kB p65 (at Lys 310) as well as panacetylated protein levels were slightly decreased in both RSV and AD groups with respect to I/R group, suggesting the ability of both RVS and AD to trigger deacetylation (S3 Fig). Nevertheless, direct evaluation of SIRT-1 deacetylating activity at the end of the three hour reperfusion interval (Fig 4) together with both functional and morphological analysis of hearts exposed to AD+STN (Figs 1–4) strongly support the involvement of SIRT-1 in AD-mediated cardiac effects. Alternatively, the discrepancy between the low SIRT-1 phosphorylation at the early post-ischemic time-point and the sustained increase of SIRT-1 activity at the end of reperfusion interval might account for a specific biological purpose, as suggested by other studies: for example, in contracting muscle in vivo and in cultured C2C12 cells incubated with AMPK activators, AMPK activation is an early event (s/min), whereas SIRT-1 activation appears to take place much later (4–12 h) [12,61] and would presumably act to sustain the activation of AMPK. Consistent with this, the low levels of phosphorylated LKB1 and AMPK observed in hearts exposed to AD+STN suggest that SIRT-1 inhibition and the subsequent impaired deacetylase ability might interfere with cytoplasmic transfer and subsequent phosphorylation of LKB1, an upstream kinase for AMPK-activation. Similar findings have been described in rat liver, where downregulation of SIRT-1 has been related to an increased lysine acetylation of LKB1, therefore preventing its translocation from the nucleus to the cytoplasm and impairing phosphorylation and activation of AMPK [24].

Conclusions

This study provides the first evidence that AD preconditioning on isolated rat hearts protects from I/R injury via a signaling pathway that involves the AMPK/LKB1/SIRT-1 axis (Fig 6). Activation of AMPK is a well known mechanism by which AD phosphorylates and activates eNOS with increased NO availability, that accounts for the majority of AD cardiovascular protective effects. By responding to changes in cellular energy state and ATP generation/consumption, AMPK activation plays a key role in modulating energy-consuming anabolic pathways [62], and can indirectly participate to SIRT-1 activation through increased NAD⁺ levels and NAD/NADH ratio [8,23]. In turn, by promoting lysine deacetylation of LKB1 and subsequent translocation from nucleus to cytoplasm, SIRT-1 may sustain the LKB1-mediated activation of AMPK [63]. Overall, results from our functional, morphological and molecular signaling experiments strongly suggest that both AMPK and SIRT-1 are required for AD-mediated cardiovascular protection, and that both these molecules act as a component of a cycle sharing common intermediated and regulating each other activities. These findings might help to shed light on mechanisms of cardiac protection by circulating endogenous
Fig 5. AD-mediated preconditioning activates AMPK, LKB1, and eNOS signaling pathways in the early post-ischemic reperfusion (15 min). Lysates from hearts exposed to 15 min of reperfusion were immunoblotted for phosphorylated and total isoforms of the indicated proteins. A. For each experimental condition, the ratio of phosphorylated/total SIRT-1, eNOS, AMPK and LKB1 proteins are expressed as the mean ± SEM of at least 3 independent experiments (each run in triplicate). Statistical differences between groups were evaluated by one-factor ANOVA followed by Bonferroni correction (*p < 0.05; **p < 0.01 vs I/R group). B. Representative immunoblots of total and phosphorylated SIRT-1, eNOS, AMPK and LKB1 proteins expression quantified in panel A are shown.

https://doi.org/10.1371/journal.pone.0210654.g005
mediators. Undoubtedly, in the prevention of heart damage resulting from acute MI, the strategy described here does not have clinical applicability. On the other hand, for cardiovascular surgery interventions that can be scheduled in advance and require a heart ischemic procedure, this might represent a potential treatment for reperfusion damages prevention. Importantly, in a clinical perspective, our findings highlight the importance of a therapeutic approach aiming at replacing endogenous AD levels in those conditions characterized by low AD concentrations and concomitant increased cardiovascular risk, including acute coronary syndrome [64], obesity-linked complications, type 2 diabetes, dyslipidemia and hypertension [32,65].
Supporting information

S1 Fig. Parameters of left ventricular function and ischemic area in hearts exposed to I/R or vehicle-I/R at the onset of ischemia. Hearts exposed to 30 min ischemia followed by 180 min reperfusion (I/R group) were compared with hearts infused with vehicle alone (3 mL/1 min; vehicle I/R) at the onset of ischemia; both functional parameters (A-D) and the extent of infarct area (E) did not significantly differ between hearts from these two groups. “Vehicle” was modified Krebs’ Henseleit solution (composed of (mmol/l): 118.5 NaCl; 4.7 KCl; 1.2 MgSO$_4$; 1.2 KH$_2$PO$_4$; 1.25 CaCl$_2$(H$_2$O); 25 NaHCO$_3$; 11 glucose) containing DMSO 0.1%.

(PPT)

S2 Fig. Left Ventricular Pressure (LVP) values in rat hearts. LVP max, indicating post-ischemic systolic functional recovery, was substantially higher in RSV group (p < 0.01 vs. I/R group, at all time-intervals), and slightly increased in AD + STN group vs. respective values in the I/R and AD groups during the second and third hour of reperfusion (p < 0.05 at 90, 120, 180 min).

(PPT)

S3 Fig. Protein acetylation levels in heart lysates. Fifteen (15) minutes after reperfusion, hearts from I/R, RSV and AD groups were prepared using lysis buffer, and samples then subjected to immunoblotting (A) or immunoprecipitation (B), according to standard methods. A: Samples were separated by 8% SDS-PAGE followed by immunoblotting with anti-acetyl NF-kB p65$_{(Lys310)}$ antibody (Cell Signaling). B. Lysates were first immunoprecipitated using an antibody against NF-kB p65 (1:50, Cell Signaling), and then subjected to immunoblotting with anti-acetyl NF-kB p65$_{(Lys310)}$ antibody (Cell Signaling). A representative blot is shown for triplicate experiments. Qualitatively, acetylation levels on NF-kB p65 (at Lys 310) appear slightly decreased in both RSV and AD groups with respect to I/R group.

(PPT)

Author Contributions

Conceptualization: Luca Sgarra, Monica Montagnani.

Data curation: Maria Assunta Potenza, Luca Sgarra, Monica Montagnani.

Formal analysis: Maria Assunta Potenza, Luca Sgarra, Valentina Leo, Maria Antonietta De Salvia, Monica Montagnani.

Investigation: Maria Assunta Potenza, Luca Sgarra, Carmela Nacci, Valentina Leo.

Methodology: Carmela Nacci, Maria Antonietta De Salvia, Monica Montagnani.

Project administration: Monica Montagnani.

Software: Carmela Nacci.

Supervision: Monica Montagnani.

Validation: Valentina Leo.

Visualization: Monica Montagnani.

Writing – original draft: Maria Assunta Potenza.

Writing – review & editing: Monica Montagnani.
References

1. Organization WH. Global status report on noncommunicable diseases 2014. 2014

2. Hausenloy DJ, Yellon DM. Ischaemic conditioning and reperfusion injury. Nat Rev Cardiol 2016; 13:193–209. https://doi.org/10.1038/nrcardio.2016.5 PMID: 26843289

3. Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R. Interaction of risk factors, comorbidities, and medications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev 2014; 66:1142–1174. https://doi.org/10.1124/pr.113.008300 PMID: 25261534

4. Rosano GM, Fini M, Caminiti G, Barbaro G. Cardiac metabolism in myocardial ischemia. Curr Pharm Des 2008; 14:2551–2562. PMID: 18991672

5. Ferrari R. Metabolic disturbances during myocardial ischemia and reperfusion. Am J Cardiol 1995; 76:17B–24B. PMID: 7645523

6. Qi D, Young LH. Ampk: Energy sensor and survival mechanism in the ischemic heart. Trends Endocrinol Metab 2015; 26:422–429. https://doi.org/10.1016/j.tem.2015.05.010 PMID: 26160707

7. Imai S, Armstrong CM, Kaebelerlein M, Guarente L. Transcriptional silencing and longevity protein sir2 is an nad-dependent histone deacetylase. Nature 2000; 403:795–800. https://doi.org/10.1038/35001622 PMID: 10693811

8. Canto C, Auwerx J. Pgc-1alpha, sirt1 and ampk, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 2009; 20:98–105. https://doi.org/10.1097/MOL.0b013e328328d0a4 PMID: 19276888

9. Finley LW, Haigis MC. The coordination of nuclear and mitochondrial communication during aging and calorie restriction. Ageing Res Rev 2009; 8:173–188. https://doi.org/10.1016/j.arr.2009.03.003 PMID: 19491041

10. Kwon HS, Ott M. The ups and downs of sirt1. Trends Biochem Sci 2008; 33:517–525. https://doi.org/10.1016/j.tibs.2008.08.001 PMID: 18805010

11. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hecking B, Kessler B, Howitz KT, Gorospe M, de Cabo R, Sinclair DA. Calorie restriction promotes mammalian cell survival by inducing the sirt1 deacetylase. Science 2004; 305:390–392. https://doi.org/10.1126/science.1099196 PMID: 15205477

12. Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, Elliott PJ, Puisserver P, Auwerx J. Ampk regulates energy expenditure by modulating nad+ metabolism and sirt1 activity. Nature 2009; 458:1056–1060. https://doi.org/10.1038/nature07813 PMID: 19262508

13. Winnik S, Stein S, Matter CM. Sirt1—an anti-inflammatory pathway at the crossroads between metabolic disease and atherosclerosis. Curr Vasc Pharmacol 2012; 10:693–696.

14. Li J, Yu S, Ying J, Shi T, Wang P. Resveratrol prevents ros-induced apoptosis in high glucose-treated retinal capillary endothelial cells via the activation of ampk/sirt1/pgc-1alpha pathway. Oxid Med Cell Longev 2017; 2017:7584691. https://doi.org/10.1155/2017/7584691

15. Kukidome D, Nishikawa T, Sonoda K, Imoto K, Fujisawa K, Yano M, Motoshima H, Taguchi T, Matsuura T, Araki E. Activation of ampk-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes 2006; 55:120–127. PMID: 16380484

16. Russell RR 3rd, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M, Giordano FJ, Mu J, Birnbaum MJ, Young LH. Amp-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 2004; 114:495–503. https://doi.org/10.1172/JCI19297 PMID: 15314866

17. Carvajal K, Zarrinparshneh E, Szarszoi O, Joubert F, Attea Y, Mateo P, Gillet B, Vaulont S, Violet B, Bigard X, Bertrand L, Ventura-Clapier R, Hoerter JA. Dual cardiac contractile effects of the alpha2-ampk deletion in low-flow ischemia and reperfusion. Am J Physiol Heart Circ Physiol 2007; 292:H3136–3147. https://doi.org/10.1152/ajpheart.00863.2006 PMID: 17337600

18. Chen ZP, Mitchelhill KI, Michell BJ, Stapleton D, Ortiz de Montellano PR, Kemp BE. Amp-activated protein kinase phosphorylation of endothelial no synthase. FEBS Lett 1999; 443:285–289. PMID: 10025949

19. Cotton JM, Kearney MT, Shah AM. Nitric oxide and myocardial function in heart failure: Friend or foe? Heart 2002; 88:564–566. PMID: 12433878

20. Heusch G, Post H, Michel MC, Kelin M, Schulz R. Endogenous nitric oxide and myocardial adaptation to ischemia. Circ Res 2000; 87:146–152. PMID: 10903999

21. Chen D, Bruno J, Easlon E, Lin SJ, Cheng HL, Alt FW, Guarente L. Tissue-specific regulation of sirt1 by calorie restriction. Genes Dev 2008; 22:1753–1757. https://doi.org/10.1101/gad.1650608 PMID: 18550784
22. Nemoto S, Fergusson MM, Finkel T. Nutrient availability regulates sirt1 through a forkhead-dependent pathway. Science 2004; 306:2105–2108. https://doi.org/10.1126/science.1101731 PMID: 15604409

23. Suwa M, Nakano H, Radak Z, Kumagai S. Endurance exercise increases the sirt1 and peroxisome proliferator-activated receptor gamma coactivator-1 alpha protein expressions in rat skeletal muscle. Metabolism 2008; 57:986–998. https://doi.org/10.1016/j.metabol.2008.02.017 PMID: 18555842

24. Lan F, Caccicedo JM, Ruderman N, Ido Y. Sir1 modulation of the acetylation status, cytosolic localization, and activity of lip1. Possible role in amp-activated protein kinase activation. J Biol Chem 2008; 283:27628–27635. https://doi.org/10.1074/jbc.M805711200 PMID: 18687677

25. Alcendor RR, Kirshenbaum LA, Imai S, Vatner SF, Sadoshima J. Silent information regulator 2 alpha, a longevity factor and class III histone deacetylase, is an essential endogenous apoptosis inhibitor in cardiac myocytes. Circ Res 2004; 95:971–980. https://doi.org/10.1161/01.RESC.0000147557.75257.ff PMID: 15486319

26. Alcendor RR, Gao S, Zhai P, Zablocki D, Holle E, Yu X, Tian B, Wagner T, Vatner SF, Sadoshima J. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res 2007; 100:1512–1521. https://doi.org/10.1161/01.RES.0000267723.65696.4a PMID: 17524229

27. Hsu CP, Zhai P, Yamamoto T, Maejima Y, Matsushita S, Harihar N, Shao D, Takagi H, Oka S, Sadoshima J. Silent information regulator 1 promotes the heart from ischemia/reperfusion. Circulation 2010; 122:2170–2182. https://doi.org/10.1161/CIRCULATIONAHA.110.958033 PMID: 21060073

28. Nadtochiy SM, Redman E, Rahaman I, Brookes PS. Lysine deacetylation in ischemic preconditioning: The role of sirt1. Cardiovasc Res 2010; 89:643–649. https://doi.org/10.1093/cvr/cvq287 PMID: 20823277

29. Nadtochiy SM, Yao H, McBurney MW, Gu W, Guante L, Rahaman I, Brookes PS. Sirt1-mediated acute cardioprotection. Am J Physiol Heart Circ Physiol 2011; 301:H1506–1512. https://doi.org/10.1152/ajpheart.00587.2011 PMID: 21856913

30. Wang L, Quan N, Sun W, Chen X, Cates C, Roussellet T, Zhou X, Zhao X, Li J. Cardiomyocyte specific deletion of sirt gene sensitizes myocardium to ischemia and reperfusion injury. Cardiovasc Res 2018

31. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Mihara H, Nakamura T, Funahashi T, Matsuzawa Y. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23:85–89. PMID: 12524229

32. Ohashi K, Kihara S, Ouchi N, Kumada M, Fujita K, Hiuge A, Hibuse T, Ryo M, Nishizawa H, Maeda N, Maeda K, Shibata R, Walsh K, Funahashi T, Shimomura I. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 2006; 47:1108–1116. https://doi.org/10.1161/01.HYP.0000223668.43759.a1 PMID: 16651465

33. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291:1730–1737. https://doi.org/10.1001/jama.291.14.1730 PMID: 15082700

34. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007; 380:24–30. https://doi.org/10.1016/j.cca.2007.01.026 PMID: 17343838

35. Addabbo F, Nacci C, De Benedictis L, Leo V, Tarquinio M, Quon MJ, Montagnani M. Globular adiponectin counteracts vcam-1-mediated monocyte adhesion via adipon1/nf-kappab/cox-2 signaling in human aortic endothelial cells. Am J Physiol Endocrinol Metab 2011; 301:E1143–1154. https://doi.org/10.1152/ajpendo.00208.2011 PMID: 216651465

36. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003; 278:45021–45026. https://doi.org/10.1074/jbc.M307787200 PMID: 12944390

37. Hattori Y, Suzuki M, Hattori S, Kasai K. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia 2003; 46:1543–1549. https://doi.org/10.1007/s00125-003-2124-3 PMID: 14551684

38. Nanayakkara G, Kariharan T, Wang L, Zhong J, Amin R. The cardio-protective signaling and mechanisms of adiponectin. Am J Cardiovasc Dis 2012; 2:253–266. PMID: 23173099

39. Gonnati AT, Widegren U, Bulhak A, Salehzadeh F, Persson J, Sjoquist PO, Pernow J. Adiponectin protects against myocardial ischemia-reperfusion injury via amp-activated protein kinase, akt, and nitric oxide. Cardiovasc Res 2008; 78:116–122. https://doi.org/10.1093/cvr/cvn007 PMID: 18222959

40. Debinski M, Buszman PP, Milewski K, Wojakowski W, Jackiewicz W, Pajak J, Szaurej D, Fryc-Stanek J, Wiernek S, Jelonek M, Bochenek A, Buszman PE. Intracoronary adiponectin at reperfusion reduces infarct size in a porcine myocardial infarction model. Int J Mol Med 2011; 27:775–781. https://doi.org/10.3892/ijmm.2011.643 PMID: 21399860
41. Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, Funahashi T, Ouchi N, Walsh K. Adiponectin protects against myocardial ischemia-reperfusion injury through ampk- and conx-2-dependent mechanisms. Nat Med 2005; 11:1096–1103. https://doi.org/10.1038/nm1295 PMID: 16155579

42. Sgarra L, Leo V, Addabbo F, Iacobazzi D, Carratu MR, Montagnani M, Potenza MA. Intermittent losartan administration triggers cardiac post-conditioning in isolated rat hearts: Role of b2k receptors. PLoS One 2014; 9:e88542. https://doi.org/10.1371/journal.pone.0088542 PMID: 24520397

43. Aksentijevic D, Lewis LH, Shattock MJ. Is rate-pressure product of any use in the isolated rat heart? Circulation 2012; 125:282–294. https://doi.org/10.1161/CIRCULATIONAHA.109.103078 PMID: 19959543

44. Li L, Wu L, Wang C, Liu L, Zhao Y. Adiponectin modulates carnitine palmitoyltransferase-1 through ampk signaling cascade in rat cardiomyocytes. Regul Pept 2007; 139:72–79. https://doi.org/10.1016/j.regpep.2006.10.007 PMID: 17109977

45. Calvert JW, Gundewar S, Jha S, Greer JJ, Bestermann WH, Tian R, Lefer DJ. Acute metformin therapy confers cardioprotection against myocardial infarction via ampk-enos-mediated signaling. Diabetes 2008; 57:696–705. https://doi.org/10.2337/db07-1098 PMID: 18083782

46. Wang Y, Gao E, Tao L, Lau WB, Yuan Y, Goldstein BJ, Lopez BL, Christopher TA, Tian R, Koch W, Ma XL. Amp-activated protein kinase deficiency enhances myocardial ischemia/reperfusion injury but has minimal effect on the antioxidant/antinitrative protection of adiponectin. Circulation 2009; 119:835–844. https://doi.org/10.1161/CIRCULATIONAHA.108.185043 PMID: 19188503

47. Chan AY, Soltyts CL, Young ME, Proud CG, Dyck JR. Activation of amp-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J Biol Chem 2004; 279:32771–32779. https://doi.org/10.1074/jbc.M403528200 PMID: 15159410
59. Cattelan A, Ceolotto G, Bova S, Albiero M, Kuppusamy M, De Martin S, Semplicini A, Fadini GP, de Kreutzemberg SV, Avogaro A. Nad(+)-dependent sirt1 deactivation has a key role on ischemia-reperfusion-induced apoptosis. Vascul Pharmacol 2015; 70:35–44. https://doi.org/10.1016/j.vph.2015.02.004 PMID: 25863291

60. Sasaki T, Maier B, Koclega KD, Chruszcz M, Gluba W, Stukenberg PT, Minor W, Scrable H. Phosphorylation regulates sirt1 function. PLoS One 2008; 3:e4020. https://doi.org/10.1371/journal.pone.0004020 PMID: 19107194

61. Fulco M, Cen Y, Zhao P, Hoffman EP, McBurney MW, Sauve AA, Sartorelli V. Glucose restriction inhibits skeletal myoblast differentiation by activating sirt1 through ampk-mediated regulation of nampt. Dev Cell 2008; 14:661–673. https://doi.org/10.1016/j.devcel.2008.02.004 PMID: 18477450

62. Young LH, Li J, Baron SJ, Russell RR. Amp-activated protein kinase: A key stress signaling pathway in the heart. Trends Cardiovasc Med 2005; 15:110–118. https://doi.org/10.1016/j.tcm.2005.04.005 PMID: 16039971

63. Hou X, Xu S, Maltland-Toolan KA, Sato K, Jiang B, Ido Y, Lan F, Walsh K, Wierzbiicki M, Verbeuren TJ, Cohen RA, Zang M. Sirt1 regulates hepatocyte lipid metabolism through activating amp-activated protein kinase. J Biol Chem 2008; 283:20015–20026. https://doi.org/10.1074/jbc.M802187200 PMID: 18482975

64. Kojima S, Funahashi T, Sakamoto T, Miyamoto S, Soejima H, Hokamaki J, Kajiwara I, Sugiyama S, Yoshimura M, Fujimoto K, Miyao Y, Suefuji H, Kitagawa A, Ouchi N, Kihara S, Matsuzawa Y, Ogawa H. The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart 2003; 89:667. PMID: 12748233

65. Nystrom T, Nygren A, Sjoholm A. Increased levels of tumour necrosis factor-alpha (tnf-alpha) in patients with type ii diabetes mellitus after myocardial infarction are related to endothelial dysfunction. Clin Sci (Lond) 2006; 110:673–681.